Press Releases

Wednesday, March 30, 2016

FDA Update to Medication Abortion Drug Label Could Improve Access to Abortion Services

Press Release
RaeAnn Roca Pickett, Senior Director of Communications & Public Affairs Phone: 202 621 1409 Email:

Mifepristone label change would align drug with best scientific evidence available and improve Latin@ access to safe, cost-effective abortion care
Washington, D.C. —Today, the United States Food and Drug Administration (FDA) announced new changes to the label for mifepristone (Mifeprex®), a medication used to end early pregnancy. The new label allows for several changes including dosage and route of administration of the drug, expansion of patient access and mitigates travel burdens faced by women by easing restrictions on in-person clinic visits for follow-up appointments. The breadth of changes to the mifepristone label reflect standard, evidence-based practices and could lead to increased access to this safe and effective drug, especially for women of color. 
Ann Marie Benitez, senior director of government relations for  NLIRH said, “The National Latina Institute for Reproductive Health applauds the FDA’s scientific and fact-based update to the mifepristone label. Abortion access is essential to ensuring the health, dignity, and justice of all people, particularly for the Latino/a. After 15 years on the US market, solid research shows that the common practice of FDA drug label updates could expand access to safely ending a pregnancy with mifepristone. Latino/a communities face significant burdens in accessing healthcare, including reproductive healthcare and we look forward to making sure all persons who choose abortion care can do so with safe, medically accurate options. We look forward to the Supreme Court’s ruling in Whole Woman’s Health v Hellerstedt to ensure access to safe abortion care is a reality for all women, regardless of where they live, and strike down HB2 in Texas.” 
The updated FDA label expands access and brings care for women more in line with modern medical practice; however, politicians in several states, including Texas under HB2 (the Texas clinic shutdown law currently before the Court), have placed medically unnecessary, politically motivated restrictions on mifepristone, curbing its availability to women. Restrictions on medical abortion do nothing to make abortion safer and instead only make abortion more costly and less available, especially to communities of color and low-income populations. 
For more information on our work in Texas, visit or follow us on Twitter @NLIRH and @TXLatinas.  
The National Latina Institute for Reproductive Health is the only national reproductive justice organization dedicated to building Latina power to advance health, dignity, and justice for 26 million Latinas, their families and communities in the United States through leadership development, community mobilization, policy advocacy, and strategic communications.